HR Execs on the Move

MEI Pharma

www.meipharma.com

 
MEI Pharma (Nasdaq: MEIP) is a San Diego-based pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer. Our approach to building our pipeline is to license promising cancer agents and create value in programs through development and commercialization, or strategic partnerships, as appropriate. Our portfolio contains four clinical-stage drug candidates, including one candidate in an ongoing global registration trial and another candidate that is anticipated to advance into a registration trial this year. Our drug candidate pipeline includes: Pracinostat, an oral HDAC inhibitor that is in a Phase 3 pivotal ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.meipharma.com
  • 3611 Valley Centre Drive Suite 500
    San Diego, CA USA 92130
  • Phone: 858.369.7100

Executives

Name Title Contact Details
Justin File
Executive Vice President of Finance and Chief Financial Officer Profile
Brian Drazba
Chief Financial Officer Profile
Brian Drazba
Chief Financial Officer Profile
Ofir Moreno
Vice President of R&D Profile
Anne Frese
Chief People Officer Profile

Similar Companies

Citra-Solv

Citra-Solv LLC is a Ridgefield, CT-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Protagonist Therapeutics

Protagonist Therapeutics is a biotechnology company pursuing the discovery and development of target oral peptides as well differentiated alternatives to antibodies, and also as new chemical entities (NCEs) against those targets and life threatening diseases for which suitable small molecule and/or biologic options are not available. Peptides typically suffer from limitations of poor proteolytic stability and therefore find scarce therapeutic utility that is largely limited to ‘injectable drugs’. Protagonist’s technology platform is aimed at overcoming these restrictions and expanding the scope of peptide therapeutics to address unmet needs. Specific emphasis is placed on identifying ‘orally stable’ scaffolds and/or engineering oral stability characteristics onto them. The platform has been optimized over the years and involves synergistic integration of rational drug design, diversity oriented computational tools, phage display libraries, recombinant peptide expression, ex vivo oral stability methods, and peptide/medicinal chemistry techniques. This activity has led to the identification of ‘privileged scaffolds’ with favorable oral stability characteristics. Furthermore, the technology platform is well suited both for de novo discovery against a target and optimization around a given chemical starting point.

Keryx

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a team of approximately 200 committed people working with passion to identify meaningful new medicines to advance the care of people with kidney disease. We have assembled a deep concentration of kidney care experts, including nephrologists, renal dietitians, nurses and industry veterans in nephrology. Together, we strive to raise awareness of the kidney disease epidemic, give voice to this underserved population, and help healthcare professionals to improve the care of their patients. In September 2014, the U.S. Food and Drug Administration approved Keryx`s first medicine, Auryxia® (ferric citrate) tablets. Keryx established its corporate headquarters in Boston`s innovation district to support the U.S. launch of Auryxia. Patients have been and continue to be at the center of our nearly 20 year corporate history.

NDD Medical Technologies

NDD Medical Technologies is a Andover, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Network Biosystems

Network Biosystems, Inc. is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.